A Double Mutation of the Ryanodine Receptor Type 1 Gene in a Malignant Hyperthermia Family with Multiminicore Myopathy
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background and Purpose:At least 100 Ryanodine receptor type 1 (RYR1) mutations associated with malignant hyperthermia (MH) and central core disease (CCD) have been identified, but 2 RYR1 mutations accompanying multiminicore myopathy in an MH and/or CCD family have been reported only rarely. Methods:Fifty-three members of a large MH family were investigated with clinical, histopathologic, RYR1 mutation, and haplotyping studies. Blood creatine kinase (CK) and myoglobin levels were also measured where possible. Results:Sequencing of the entire RYR1 coding region identified a double RYR1 mutation (R2435H and A4295V) in MH/CCD regions 2 and 3. Haplotyping analysis revealed that the two missense heterozygous mutations (c.7304G>A and c.12891C>T) were always present on a common haplotype allele, and were closely cosegregated with histological multiminicores and elevated serum CK. All the subjects with the double mutation showed elevated serum CK and myoglobin, and the obtained muscle biopsy samples showed multiminicore lesions, but only two family members presented a late-onset, slowly progressive myopathy. Conclusions:We found multiminicore myopathy with clinical and histological variability in a large MH family with an unusual double RYR1 mutation, including a typical CCD-causing known mutant. These results suggest that multiminicore lesions are associated with the presence of more than two mutations in the RYR1 gene.
Abstract
Background and Purpose:At least 100 Ryanodine receptor type 1 (RYR1) mutations associated with malignant hyperthermia (MH) and central core disease (CCD) have been identified, but 2 RYR1 mutations accompanying multiminicore myopathy in an MH and/or CCD family have been reported only rarely. Methods:Fifty-three members of a large MH family were investigated with clinical, histopathologic, RYR1 mutation, and haplotyping studies. Blood creatine kinase (CK) and myoglobin levels were also measured where possible. Results:Sequencing of the entire RYR1 coding region identified a double RYR1 mutation (R2435H and A4295V) in MH/CCD regions 2 and 3. Haplotyping analysis revealed that the two missense heterozygous mutations (c.7304G>A and c.12891C>T) were always present on a common haplotype allele, and were closely cosegregated with histological multiminicores and elevated serum CK. All the subjects with the double mutation showed elevated serum CK and myoglobin, and the obtained muscle biopsy samples showed multiminicore lesions, but only two family members presented a late-onset, slowly progressive myopathy. Conclusions:We found multiminicore myopathy with clinical and histological variability in a large MH family with an unusual double RYR1 mutation, including a typical CCD-causing known mutant. These results suggest that multiminicore lesions are associated with the presence of more than two mutations in the RYR1 gene.
참고문헌 (37)
- Denborough M, "Malignant hyperthermia", Lancet, 352, pp.1131~1136 (1998)
- Hopkins PM, "Malignant hyperthermia: advances in clinical management and diagnosis", Br J Anaesth, 85, pp.118~128 (2000)
- Quinlivan RM, "Central core disease: clinical, pathological, and genetic features", Arch Dis Child, 88, pp.1051~1055 (2003)
- Sewry CA, "The spectrum of pathology in central core disease", Neuromuscul Disord, 12, pp.930~938 (2002)
- Mertz KD, "Progressive scoliosis in central core disease", Eur Spine J, 14, pp.900~905 (2005)
- Jurkat-Rott K, "Genetics and pathogenesis of malignant hyperthermia", Muscle Nerve, 23, pp.4~17 (2000)
- Robinson RL, "Multiple interacting gene products may influence susceptibility to malignant hyperthermia", Ann Hum Genet, 64, pp.307~320 (2000)
- MacLennan DH, "Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia", Nature, 343, pp.559~561 (1990)
- McCarthy TV, "Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2", Nature, 343, pp.562~564 (1990)
- Kausch K, "Evidence for linkage of the central core disease locus to the proximal long arm of human chromosome 19", Genomics, 10, pp.765~769 (1991)
- Takeshima H, "Primary structure and expression from complementary DNA of skeletal muscle ryanodine receptor", Nature, 339, pp.439~445 (1989)
- Zorzato F, "Molecular cloning of cDNA encoding human and rabbit forms of the Ca2+ release channel (ryanodine receptor) of skeletal muscle sarcoplasmic reticulum", J Biol Chem, 265, pp.2244~2256 (1990)
- Phillips MS, "The structural organization of the human skeletal muscle ryanodine receptor (RYR1) gene", Genomics, 34, pp.24~41 (1996)
- Brini M, "Ca2+ signaling in HEK-293 and skeletal muscle cells expressing recombinant ryanodine receptors harboring malignant hyperthermia and central core disease mutations", J Biol Chem, 280, pp.15380~15389 (2005)
- Sambuughin N, "Screening of the entire ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia susceptibility in the north american population", Anesthesiology, 102, pp.515~521 (2005)
- Brandom BW, "XXIVth Annual Meeting of the European Malignant Hyperthermia Group", Anesthesiology, 103, pp.1324~ (2005)
- Larach MG, "A clinical grading scale to predict malignant hyperthermia susceptibility", Anesthesiology, 80, pp.771~779 (1994)
- Kim JS, "Malignant hyperthermia during general anesthesia (a case report)", Korean J Anesthesiol, 14, pp.313~318 (1981)
- Higasa K, "Ordered catenation of sequence-tagged sites and multiplexed SNP genotyping by sequencing", Nucleic Acids Res, 30, pp.E11~ (2002)
- Zhang Y, "A mutation in the human ryanodine receptor gene associated with central core disease", Nat Genet, 5, pp.46~50 (1993)
- Monnier N, "Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility", Anesthesiology, 97, pp.1067~1074 (2002)
- Romero NB, "Malignant hyperthermia and central core disease: analysis of two families with heterogeneous clinical expression", Neuromuscul Disord, 3, pp.547~551 (1993)
- Urwyler A, "European Malignant Hyperthermia Group. Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia", Br J Anaesth, 86, pp.283~287 (2001)
- Treves S, "Ryanodine receptor 1 mutations, dysregulation of calcium homeostasis and neuromuscular disorders", Neuromuscul Disord, 15, pp.577~587 (2005)
- Lynch PJ, "Identification of heterozygous and homozygous individuals with the novel RYR1 mutation Cys35Arg in a large kindred", Anesthesiology, 86, pp.620~626 (1997)
- Rueffert H, "Homozygous and heterozygous Arg614Cys mutations (1840C-->T) in the ryanodine receptor gene co-segregate with malignant hyperthermia susceptibility in a German family", Br J Anaesth, 87, pp.240~245 (2001)
- Guis S, "Multiminicore disease in a family susceptible to malignant hyperthermia: histology, in vitro contracture tests, and genetic characterization", Arch Neurol, 61, pp.106~113 (2004)
- Shuaib A, "Central core disease. Clinical features in 13 patients", Medicine (Baltimore), 66, pp.389~396 (1987)
- Sei Y, "Malignant hyperthermia genetic testing in North America Working Group Meeting", Anesthesiology, 100, pp.464~465 (2004)
- Gillard EF, "Polymorphisms and deduced amino acid substitutions in the coding sequence of the ryanodine receptor (RYR1) gene in individuals with malignant hyperthermia", Genomics, 13, pp.1247~1254 (1992)
- McCarthy TV, "Ryanodine receptor mutations in malignant hyperthermia and central core disease", Hum Mutat, 15, pp.410~417 (2000)
- Tilgen N, "Identification of four novel mutations in the C-terminal membrane spanning domain of the ryanodine receptor 1: association with central core disease and alteration of calcium homeostasis", Hum Mol Genet, 10, pp.2879~2887 (2001)
- Monnier N, "Correlations between genotype and pharmacological, histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility", Hum Mutat, 26, pp.413~425 (2005)
- Shepherd S, "RYR1 mutations in UK central core disease patients: more than just the C-terminal transmembrane region of the RYR1 gene", J Med Genet, 41, pp.e33.~ (2004)
- Mathews KD, "Multiminicore myopathy, central core disease, malignant hyperthermia susceptibility, and RYR1 mutations: one disease with many faces", Arch Neurol, 61, pp.27~29 (2004)
- Lamont PJ, "Fifty year follow-up of a patient with central core disease shows slow but definite progression", Neuromuscul Disord, 8, pp.385~391 (1998)
- Kraev N, "Protocol for the sequence analysis of ryanodine receptor subtype 1 gene transcripts from human leukocytes", Anesthesiology, 99, pp.289~296 (2003)